The U.S. Health and Human Services (HHS) is expanding access to six unproven peptides, substances that have not been evaluated for safety or efficacy by the FDA. This policy shift, championed by HHS Secretary Robert F. Kennedy Jr., allows specialized compounding pharmacies to sell these peptides, often marketed for weight loss, muscle building, and longevity. Despite warnings from FDA scientists about insufficient safety and efficacy data, a committee advised by Kennedy, with members linked to peptide businesses, voted to increase access. This move effectively permits pharmacies to sell these substances under a policy of "enforcement discretion," meaning the FDA will not pursue legal consequences. AI
RANK_REASON Policy change by a US federal agency impacting public health and regulation. [lever_c_demoted from significant: ic=1 ai=0.1]
- BPC-157
- Épitalon
- Health and Human Services
- Marvel
- MOTS-c
- Ozempic
- Robert F. Kennedy Jr.
- Semax
- TB-500
- United States Food and Drug Administration
- Wegovy
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →